Details checkedClinical trial listing onlyCheckedregistry

Hannover ESCRT intracochlear VSF1.01 cochlear-implant trauma study

Also known as: Intracochlear Application Of Vsf1.01, VSF1.01, ESCRT, hUC-MSC-EVs, NCT06545175, 2024-512498-29-00

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Cell Therapy

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Intracochlear application during cochlear implantation

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

Germany

Population

adult, cochlear-implant, profound, cell-derived-extracellular-vesicles

Trial IDs

Mechanism

Intracochlear extracellular-vesicle-enriched secretome fraction VSF1.01, enriched with human umbilical-cord mesenchymal-stromal-cell extracellular vesicles, administered during cochlear implantation to reduce surgery-related cochlear trauma.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

Corrected modality and stage. The registry describes an open-label Hannover Medical School Phase I/IIa trial of intracochlear VSF1.01, an extracellular-vesicle-enriched secretome fraction, in cochlear implantation. This is institution-led and should not be displayed as a company product row.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, modality...

IDs: NCT06545175, ESCRT, VSF1.01, 2024-512498-29-00

Open

Key Events

2024-08-09

ESCRT intracochlear VSF1.01 trial first posted

2026-02-12

ClinicalTrials.gov update lists ESCRT as recruiting

Clinical Trials (1)